Plasma therapy: a passive resistance against the deadliest

References

• Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transf. 2016;14(2):1. doi:https://doi.org/10.2450/2015.0131-15.
   PubMedGoogle Scholar
• Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma. Vox Sang. 2020;115(6):485–10. doi:https://doi.org/10.1111/vox.12939.
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, Makki S, Rooney KD, Group CPS, Nguyen-Van-Tam JS. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi:https://doi.org/10.1093/infdis/jiu396.
   PubMed Web of Science ®Google Scholar
• MaizteguiJ, Fernandez N, De Damilano A. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;314(8154):1216–17. doi:https://doi.org/10.1016/S0140-6736(79)92335-3.
   Google Scholar
• Kaufmann SH. Remembering Emil von behring: from tetanus treatment to antibody cooperation with phagocytes. Am Soc Microbiol. 2017. doi:https://doi.org/10.1128/mBio.00117-17.
   Google Scholar
• Hifumi T, Yamamoto A, Ato M, Sawabe K, Morokuma K, Morine N, Kondo Y, Noda E, Sakai A, Takahashi J. Clinical serum therapy: benefits, cautions, and potential applications. Keio J Med. 2017:2016–0017-IR. doi:https://doi.org/10.2302/kjm.2016-0017-IR.
   Google Scholar
• Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38(8):1695. doi:https://doi.org/10.1128/AAC.38.8.1695.
   PubMed Web of Science ®Google Scholar
• LukeTC, Casadevall A, Watowich SJ, HoffmanSL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38:e66–e73. doi:https://doi.org/10.1097/CCM.0b013e3181d44c1e.
   PubMed Web of Science ®Google Scholar
• Ahmed SM, AhmedM, Nadeem A, Mahajan J, Choudhary A, Pal J. Emergency treatment of a snake bite: pearls from literature. J Emerg Trauma Shock. 2008;1(2):97. doi:https://doi.org/10.4103/0974-2700.43190.
   PubMedGoogle Scholar
• Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:https://doi.org/10.1016/j.autrev.2020.102554.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–24. doi:https://doi.org/10.1038/s41586-020-2179-y.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, ZhouY, Liu S, ZhengB-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–36. doi:https://doi.org/10.1038/nrmicro2090.
   PubMed Web of Science ®Google Scholar
• Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett. 2009;125(2):79–85. doi:https://doi.org/10.1016/j.imlet.2009.06.003.
   PubMed Web of Science ®Google Scholar
• Brioen P, Dekegel D, Boeye A. Neutralization of poliovirus by antibody-mediated polymerization. Virology. 1983;127(2):463–68. doi:https://doi.org/10.1016/0042-6822(83)90159-9.
   PubMed Web of Science ®Google Scholar
• Tatum W, Elliott J, Nesset N. The use of plasma as a substitute for whole blood. J Am Soc Anesthesiologists. 1940:363–66. doi:https://doi.org/10.1097/00000542-194011000-00030.
   Google Scholar
• Dasaraju PV, and Liu C. Infections of the respiratory system. Medical microbiology. 4th ed; Galveston (TX): Univesity of Texas Medical Branch at Galveston;1996. PMID: 21413304.
   Google Scholar
• Johnston S, and Holgate S. Epidemiology of viral respiratory tract infections. Viral and other infections of the human respiratory tract. London, UK: Springer; 1996. p. 1–38.
   Google Scholar
• Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609. doi:https://doi.org/10.7326/0003-4819-145-8-200610170-00139.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, LeeC-K, Lee K-L, ChanK, Yan -W-W, Liu R, Watt C-L, Chan W-M, Lai K-Y. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–56. doi:https://doi.org/10.1093/cid/ciq106.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Kam CW, Mak YK. Update: isolation of avian influenza A(H5N1) viruses from human beings–Hong Kong, 1997-1998. Ann Emerg Med. 1998;31:647–49. PMID: 9581152.
   PubMed Web of Science ®Google Scholar
• Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: discovery, diagnostics and drug development. J Hepatol. 2020. doi:https://doi.org/10.1016/j.jhep.2020.09.031.
   Google Scholar
• Wong V, Dai D, Wu A, Sung J. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003;9:199–201. PMID: 12777656.
   PubMedGoogle Scholar
• Ko J-H, Seok H, Cho SY, Ha YE, Baek JY, KimSH, Kim Y-J, Park JK, Chung CR, KangE-S. Challenges of convalescent plasma infusion therapy in middle east respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–22. doi:https://doi.org/10.3851/IMP3243.
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol. 2001;75(10):4649–54. doi:https://doi.org/10.1128/JVI.75.10.4649-4654.2001.
   PubMed Web of Science ®Google Scholar
• Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba NF, Antierens A. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:https://doi.org/10.1056/NEJMoa1511812.
   PubMed Web of Science ®Google Scholar
• Brown JF, Dye JM, Tozay S, Jeh-Mulbah G, Wohl DA, Fischer WA 2nd, Cunningham CK, Rowe K, Zacharias P, van Hasselt J. Anti–Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease. J Infect Dis. 2018;218(4):555–62. doi:https://doi.org/10.1093/infdis/jiy199.
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985;79(3):380–84. doi:https://doi.org/10.1016/0035-9203(85)90388-8.
   PubMed Web of Science ®Google Scholar
• Maiztegui JI, McKee KT Jr, Oro JGB, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, LevisSC, AmbrosioAM. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis. 1998;177(2):277–83. doi:https://doi.org/10.1086/514211.
   PubMed Web of Science ®Google Scholar
• Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, and Crivelli E. VACUNA CONTRA LA FIEBRE HEMORRAGICA ARGENTINA CANDID# 1 PRODUCIDA EN LA ARGENTINA. INMUNOGENICIDAD Y SEGURIDAD. MEDICINA (Buenos Aires). 2010;70:215–222 . PMID: 20529769.
   PubMed Web of Science ®Google Scholar
• Enria D, Fernandez N, Briggiler A, Levis S, MaizteguiJ. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;324(8397):255–56. doi:https://doi.org/10.1016/s0140-6736(84)90299-x.
   Google Scholar
• Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994;23(1):23–31. doi:https://doi.org/10.1016/0166-3542(94)90030-2.
   PubMed Web of Science ®Google Scholar
• Enria DA, Briggiler AM, SánchezZ. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78(1):132–39. doi:https://doi.org/10.1016/j.antiviral.2007.10.010.
   PubMed Web of Science ®Google Scholar
• Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, Tomicic V, Graf J, Paredes L, Florenzano M. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV. Antivir Ther. 2014;20(4):377–86. doi:https://doi.org/10.3851/IMP2875.
   PubMed Web of Science ®Google Scholar
• Wang S, HongS, Deng Y-Q, Ye Q, Zhao L-Z, ZhangF-C, Qin C-F, XuZ. Transfer of convalescent serum to pregnant mice prevents Zika virus infection and microcephaly in offspring. Cell Res. 2017;27(1):158–60. doi:https://doi.org/10.1038/cr.2016.144.
   PubMed Web of Science ®Google Scholar
• Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin J, Purcell RH. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Nat Acad Sci. 1994;91(21):10198–202. doi:https://doi.org/10.1073/pnas.91.21.10198.
   PubMed Web of Science ®Google Scholar
• Abolghasemi H, Eshghi P, Cheraghali AM, Fooladi AAI, Moghaddam FB, Imanizadeh S, Maleki MM, Ranjkesh M, Rezapour M, Bahramifar A. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transf Apheresis Sci. 2020;59(5):102875. doi:https://doi.org/10.1016/j.transci.2020.102875.
   PubMed Web of Science ®Google Scholar
• Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. Early mortality benefit with COVID‐19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–13. doi:https://doi.org/10.1111/bjh.17272.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–89. doi:https://doi.org/10.1001/jama.2020.4783.
   PubMed Web of Science ®Google Scholar
• Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transf Apheresis Sci. 2020;59(5):102867. doi:https://doi.org/10.1016/j.transci.2020.102867.
   PubMed Web of Science ®Google Scholar
• Ye M, Fu D, RenY, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890–901. doi:https://doi.org/10.1002/jmv.25882.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, Zhang H, YuT, Qu J, Zhou M, Chen L, Meng S, HuY. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020;117(17):9490–96. doi:https://doi.org/10.1073/pnas.2004168117.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–18. doi:https://doi.org/10.1056/NEJMoa2033700.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez M. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–29. doi:https://doi.org/10.1056/NEJMoa2031304.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. Jama. 2020;324(5):460–70. doi:https://doi.org/10.1001/jama.2020.10044.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M, Vizcaya C, Mondaca S, Huete Á. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial. PLoS Med. 2021;18(3):e1003415. doi:https://doi.org/10.1371/journal.pmed.1003415.
   PubMed Web of Science ®Google Scholar
• Zeng Q-L, Yu Z-J, Gou -J-J, Li G-M, MaS-H, Zhang G-F, Xu J-H, LinW-B, CuiG-L, Zhang -M-M. Effect of convalescent plasma therapy on viral shedding and survival in patients with Coronavirus disease 2019. J Infect Dis. 2020;222(1):38–43. doi:https://doi.org/10.1093/infdis/jiaa228.
   PubMed Web of Science ®Google Scholar
• Arumugham VB, and Rayi A. Intravenous Immunoglobulin (IVIG). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Salemi S, Markovic M, Martini G, D’Amelio R. The expanding role of therapeutic antibodies. Int Rev Immunol. 2015;34(3):202–64. doi:https://doi.org/10.3109/08830185.2013.863304.
   PubMed Web of Science ®Google Scholar
• Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat J-M, Magy L, Bayry J, Kaveri SV. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients. Immunol Res. 2014;60(2–3):320–29. doi:https://doi.org/10.1007/s12026-014-8580-6.
   PubMed Web of Science ®Google Scholar
• Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P, GdÉdTd PTAI. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg bw. Br J Haematol. 1999;107:716–19. doi:https://doi.org/10.1046/j.1365-2141.1999.01766.x.
   PubMed Web of Science ®Google Scholar
• Roifman C, Levison H, Gelfand E. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;329(8541):1075–77. doi:https://doi.org/10.1016/S0140-6736(87)90494-6.
   Google Scholar
• Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):705–12. doi:https://doi.org/10.1056/NEJM199009133231103.
   PubMed Web of Science ®Google Scholar
• Jolles S, Sewell W, Misbah S. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1. doi:https://doi.org/10.1111/j.1365-2249.2005.02834.x.
   PubMed Web of Science ®Google Scholar
• Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE, Group CSS. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. Clin Infect Dis. 1999;28:800–07. doi:https://doi.org/10.1086/515199.
   PubMed Web of Science ®Google Scholar
• Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, Mciver J, Siber GR. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J. 1999;18(6):505–11. doi:https://doi.org/10.1097/00006454-199906000-00006.
   PubMed Web of Science ®Google Scholar
• Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–14. doi:https://doi.org/10.1128/CMR.13.4.602.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub–Saharan Africa. J Infect Dis. 2017;215(9):1362–65. doi:https://doi.org/10.1093/infdis/jix089.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer III WA, Shearer WT, Hawkins E. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000;181:548–54. doi:https://doi.org/10.1086/315224.
   PubMed Web of Science ®Google Scholar
• Bharti OK, Madhusudana SN, Wilde H. Injecting rabies immunoglobulin (RIG) into wounds only: a significant saving of lives and costly RIG. Hum Vaccin Immunother. 2017;13(4):762–65. doi:https://doi.org/10.1080/21645515.2016.1255834.
   PubMed Web of Science ®Google Scholar
• Sapir T, Shoenfeld Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin Rev Allergy Immunol. 2005;29(3):307–10. doi:https://doi.org/10.1385/CRIAI:29:3:307.
   PubMed Web of Science ®Google Scholar
• Flicker S, Linhart B, Wild C, Wiedermann U, Valenta R. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology. 2013;218(6):884–91. doi:https://doi.org/10.1016/j.imbio.2012.10.008.
   PubMed Web of Science ®Google Scholar
• Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, Koscumb S, Collins K, Schmidhofer M, Shovel JA. Impact of Bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection. Open forum infectious diseases: Oxford University Press US; 2021. ofab254. doi:https://doi.org/10.1093/ofid/ofab254.
   Google Scholar
• Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325(7):632–44. doi:https://doi.org/10.1001/jama.2021.0202.
   PubMed Web of Science ®Google Scholar
• Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–42. doi:https://doi.org/10.1126/science.aad5224.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019;393(10174):889–98. doi:https://doi.org/10.1016/S0140-6736(19)30036-4.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303. doi:https://doi.org/10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–39. doi:https://doi.org/10.1093/cid/ciaa237.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. NEngl J Med. 2020;383(6):517–25. doi:https://doi.org/10.1056/NEJMoa2016638.
   PubMed Web of Science ®Google Scholar
• Group RC. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:https://doi.org/10.1056/NEJMoa2021436.
   PubMed Web of Science ®Google Scholar
• Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, Tinelli MA, Cimino RO, Álvarez L. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClinicalMed. 2021;37:100959. doi:https://doi.org/10.1016/j.eclinm.2021.100959.
   PubMedGoogle Scholar
• Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185–91. doi:https://doi.org/10.1038/s41564-020-00789-5.
   PubMed Web of Science ®Google Scholar
• Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi S-R, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20(1):786. doi:https://doi.org/10.1186/s12879-020-05507-4.
   PubMed Web of Science ®Google Scholar
• Raman RS, Bhagwan Barge V, Anil Kumar D, Dandu H, Rakesh Kartha R, Bafna V, Aravinda VT, Raghuram TC. A Phase II safety and efficacy study on prognosis of moderate pneumonia in Coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis. 2021;223(9):1538–43. doi:https://doi.org/10.1093/infdis/jiab098.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L, et al. High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China. Front Immunol. 2021;12. doi:https://doi.org/10.3389/fimmu.2021.627844.
   Google Scholar
• Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev. 2020;33(4):e00072–20. doi:https://doi.org/10.1128/CMR.00072-20.
   PubMed Web of Science ®Google Scholar
• Nagoba B, Gavkare A, Jamadar N, Mumbre S, Selkar S. Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19. J Infect Public Health. 2020;13(12):1818–22. doi:https://doi.org/10.1016/j.jiph.2020.08.011.
   PubMed Web of Science ®Google Scholar